The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the …

Cetuximab has an established role in the treatment of patients with recurrent/metastatic
colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long …

Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Natural killer (NK) cells are emerging as unique players in the immune response against
cancer; however, only limited data are available on tumor infiltrating NK cells in head and …

The pattern of clinical behaviour and response to treatment of recurrent and/or metastatic
head and neck squamous cell carcinoma is heterogeneous. Treatment strategies that can …

Background The epidermal growth factor receptor (EGFR) is overexpressed by 80–90% of
squamous cell carcinoma of head and neck (HNSCC). In addition to inhibiting EGFR signal …

Simple Summary According to the latest GLOBOCAN data, head and neck squamous cell
carcinoma (HNSCC) represents the sixth most prevalent human malignancy. Recent studies …

Background Epidermal growth factor receptor (EGFR) is frequently overexpressed in oral
squamous cell carcinoma (OSCC), and EGFR‐targeting therapeutics have been widely …

A variety of systemic chemotherapy regimens have been used for recurrent/metastatic head
and neck squamous cell carcinoma (R/M HNSCC). However, most guidelines have been …